How does ‘comparability’ apply to biosimilar drug development? This was the question discussed by Dr Mark McCamish and Dr Gillian Woollett [1].
Comparability for biosimilar development
Biosimilars/Research | Posted 13/05/2011 0 Post your comment
The FDA uses the term ‘comparability’ only when referring to changes in the manufacturing process for originator biologicals. The term ‘highly similar’ is used when referring to the comparison of an originator or reference product to a biosimilar. The methods and analytical tools used, however, in both cases are the same.
The need for ‘comparability’ studies became necessary due to the increased demand for biologicals in the 1990s. This made scale up of manufacturing processes necessary, often leading to changes in the process or even moving site.
There was therefore a need to evaluate these products pre- and post-manufacturing change, leading to the term ‘comparability’ for biologicals. Evidence of ‘comparability’ then leads to interchangeability of the products without the need for (in most cases) clinical trials.
In Europe the term ‘comparability’ was extended to products from different sponsors in 2003 and became the basis for the EMAs approach to regulatory approval of biosimilars, and is also being used for post-approval manufacturing changes to biosimilars in Europe and elsewhere.
In the US, although, as of March 2010, a legal pathway exists for the approval of biosimilars, practical guidance from the FDA is still anticipated, but one thing is for sure ‘comparability’ or ‘highly similar’ is certain to be part of this guidance.
Related articles
Need for a global pathway for biosimilars
Interchangeability or substitution of biosimilars
Regulatory approach to biosimilar development
Opportunities for biosimilar development
Worldwide biosimilar development
Global biosimilar market to grow to US$3.7 billion in 2015
Reference
1. McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209-17. doi:10.4161/mabs.3.2.15005
News
First denosumab biosimilars approved in Canada and the US
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
General
Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe
Insurer perspective on increasing biosimilar uptake in Canada
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
ANVISA's role in biosimilar medicine regulation and innovation promotion
Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
Comments (0)
Post your comment